Skip to Content
Søk Menu
Sara Tolaney

ASCO 2025: Redefining First-Line Therapy in HER2+ Breast Cancer with T-DXd and Pertuzumab

/ Sara Tolaney
ASCO25BrystkreftNBCN Play the Video
Ioannis Zerdes

Multidimensional Profiling of Immune Micro- and Macro-Environment in Early Breast Cancer Treated with Neoadjuvant Therapy

/ Ioannis Zerdes
BrystkreftNBCN Play the Video
Irma Frederiksson & Tove Filtenborg Tvedskov

Clinical Controversies in Axillary Management in Breast Cancer

/ Irma Frederiksson / Tove Filtenborg Tvedskov
BrystkreftNBCN Play the Video
Tobias Berg

Increased Need for Improvement in the Treatment of Non-Luminal A Subtype Metastatic Breast Cancer in First-Line Treatment

/ Tobias Berg
BrystkreftNBCN Play the Video
Kristine Wiborg Høgsbjerg

Boost vs Surgery: Breast Induration Risk

/ Kristine Wiborg Høgsbjerg
Brystkreft Play the Video
Per Hall

Making Primary Breast Cancer Prevention a Reality

/ Per Hall
Brystkreft Play the Video

The Impact of Abemaciclib in Treating HR-Positive HER2-Negative Breast Cancer

/ Amanda Feldballe Bernholm
Brystkreft
Philip Poortmans

Breast Cancer Treatment: The Role of Boost Radiation Therapy in Reducing Recurrence Risks

/ Philip Poortmans
BrystkreftOnkologisk Forum 2024 Play the Video
Demet Özcan

Breast Cancer: The Prognostic Value of Tumor-Infiltrating Lymphocytes

/ Demet Özcan
BrystkreftSABCS24 Play the Video
Hope Rugo

Abemaciclib Shows Significant Benefit for HR-Positive HER2-Negative Patients with Advanced Breast Cancer

/ Hope S. Rugo
Brystkreft Play the Video
Maren Marie Andreassen

MRI-Based AI Can Detect Responsive Treatment of Breast Cancer After Three Weeks of Therapy

/ Maren Marie Andreassen
BrystkreftNBCN Play the Video
Adam Brufsky

SABCS 2024: Palbociclib, Abemaciclib, and Ribociclib Can Be Considered Equivalent in the Treatment of HR-Positive/HER2-Negative Metastatic Breast Cancer

/ Adam Brufsky
BrystkreftSABCS24 Play the Video
Hent flere
Back to top